Tenaya Therapeutics, Inc. Earnings Per Share (Basic)
Tenaya Therapeutics, Inc. (TNYA) reported Earnings Per Share (Basic) of -$0.20 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- Tenaya Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.20.
- Tenaya Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.09.
- Tenaya Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.12.
- Tenaya Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.12.
- Tenaya Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.59.
- Tenaya Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.31.
- Tenaya Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$1.68.
- Tenaya Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.76.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.20 10-Q · filed 2026-08-05 | -$0.29 10-Q · filed 2026-08-05 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.09 10-Q · filed 2026-05-06 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.59 10-K · filed 2026-03-11 |
| 2025-09-30 | -$0.12 10-Q · filed 2025-11-10 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.48 10-Q · filed 2025-11-10 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.14 10-Q · filed 2026-08-05 | -$0.37 10-Q · filed 2026-08-05 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.24 10-Q · filed 2026-05-06 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-03-11 | -$1.31 10-K · filed 2026-03-11 |
| 2024-09-30 | -$0.30 10-Q · filed 2025-11-10 | -$0.64 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.04 10-Q · filed 2025-11-10 | -$1.43 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-06-30 | -$0.34 10-Q · filed 2025-08-06 | -$0.74 10-Q · filed 2025-08-06 | -$1.14 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.53 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2024-03-31 | -$0.40 10-Q · filed 2025-05-07 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.19 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.65 derived: net income ÷ weighted average shares · filed 2025-11-10 |
| 2023-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$1.25 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$1.68 10-K · filed 2025-03-10 |
| 2023-09-30 | -$0.39 10-Q · filed 2024-11-06 | -$0.85 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.28 10-Q · filed 2024-11-06 | -$1.85 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-06-30 | -$0.45 10-Q · filed 2024-08-08 | -$0.89 10-Q · filed 2024-08-08 | -$1.46 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$2.13 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-03-31 | -$0.43 10-Q · filed 2024-05-14 | -$1.02 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.70 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$2.36 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2022-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$1.33 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$2.01 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$2.76 10-K · filed 2024-03-18 |
| 2022-09-30 | -$0.74 10-Q · filed 2023-11-08 | -$1.43 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.18 10-Q · filed 2023-11-08 | -$2.81 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2022-06-30 | -$0.69 10-Q · filed 2023-08-09 | -$1.44 10-Q · filed 2023-08-09 | -$2.07 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.75 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2022-03-31 | -$0.75 10-Q · filed 2023-05-10 | -$1.38 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$2.06 derived: net income ÷ weighted average shares · filed 2023-11-08 | |
| 2021-12-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$1.30 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$4.10 10-K · filed 2023-03-08 | |
| 2021-09-30 | -$0.68 10-Q · filed 2022-11-10 | -$4.75 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |